ZURA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.188

+135.41%

-0.190

-0%

-0.200

+17.65%

Estimates Revision

The market is revising No Change the revenue expectations for Zura Bio Limited (ZURA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 112.50%.

EPS Estimates for FY2025

Revise Upward

+4.45%

In Past 3 Month

Stock Price

Go Up

+112.50%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 11.67 USD with a low forecast of 2.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 4.080

Low

2.00

Averages

11.67

High

18.00

Current: 4.080

Low

2.00

Averages

11.67

High

18.00

Clear Street

NULL

Buy

initiated

$18

2025-11-12

Reason

Clear Street

Price Target

$18

2025-11-12

initiated

NULL

Buy

Reason

Clear Street initiated coverage of Zura Bio with a Buy rating and $18 price target. The firm said he rating reflects "strong conviction" in tibulizumab's ability to lead in hidradenitis suppurativa and systemic sclerosis. The firm also believes tibulizumab is well positioned to set a new standard.

H.C. Wainwright

Neutral

downgrade

$3 -> $2

2025-08-19

Reason

H.C. Wainwright

Price Target

$3 -> $2

2025-08-19

downgrade

Neutral

Reason

H.C. Wainwright lowered the firm's price target on Zura Bio to $2 from $3 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q2 report to reflect increases in potentially dilutive shares outstanding.

Oppenheimer

Outperform

downgrade

$17 -> $16

2025-08-15

Reason

Oppenheimer

Price Target

$17 -> $16

2025-08-15

downgrade

Outperform

Reason

Oppenheimer lowered the firm's price target on Zura Bio to $16 from $17 and keeps an Outperform rating on the shares after the company reported Q2 financial results and provided an update on their ongoing clinical studies of tibulizumab, with the global Phase 2 TibuSHIELD study in HS having launched in May. The firm's reported Q2 ending cash of $154.5M is anticipated to support operations through 2027 and readouts from both ongoing studies of tibulizumab.

Oppenheimer

Outperform

downgrade

$19 -> $17

2025-05-09

Reason

Oppenheimer

Price Target

$19 -> $17

2025-05-09

downgrade

Outperform

Reason

Oppenheimer lowered the firm's price target on Zura Bio to $17 from $19 and keeps an Outperform rating on the shares. The firm notes Zura reported Q1 results with tibulizumab continuing to advance. The Phase 2 TibuSURE trial in SSC is active with efforts focused on site contracting and activation. Next up the HS study is slated to begin Q2 2025.

HC Wainwright & Co.

Mitchell Kapoor

Hold

Maintains

$5 → $3

2025-04-03

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$5 → $3

2025-04-03

Maintains

Hold

Reason

Chardan Capital

Matthew Barcus

Strong Buy

Maintains

$12 → $10

2025-03-26

Reason

Chardan Capital

Matthew Barcus

Price Target

$12 → $10

2025-03-26

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Zura Bio Ltd (ZURA.O) is -5.19, compared to its 5-year average forward P/E of -4.60. For a more detailed relative valuation and DCF analysis to assess Zura Bio Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.60

Current PE

-5.19

Overvalued PE

-1.82

Undervalued PE

-7.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ZURA News & Events

Events Timeline

No data

News

6.0

11-14Benzinga

Chardan Capital Reaffirms Buy Rating on Zura Bio with $10 Price Target Intact

9.5

11-13Newsfilter

Zura Bio Announces Financial Results for Q3 2025 and Latest Corporate Developments

9.0

10-24NASDAQ.COM

INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading

People Also Watch

Frequently Asked Questions

What is Zura Bio Ltd (ZURA) stock price today?

The current price of ZURA is 4.08 USD — it has increased 1.49 % in the last trading day.

What is Zura Bio Ltd (ZURA)'s business?

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

What is the price predicton of ZURA Stock?

What is Zura Bio Ltd (ZURA)'s revenue for the last quarter?

Zura Bio Ltd revenue for the last quarter amounts to -19.52M USD, increased 1.04 % YoY.

What is Zura Bio Ltd (ZURA)'s earnings per share (EPS) for the last quarter?

Zura Bio Ltd. EPS for the last quarter amounts to -15476000.00 USD, increased 173.14 % YoY.

What changes have occurred in the market's expectations for Zura Bio Ltd (ZURA)'s fundamentals?

How many employees does Zura Bio Ltd (ZURA). have?

Zura Bio Ltd (ZURA) has 30 emplpoyees as of December 15 2025.

What is Zura Bio Ltd (ZURA) market cap?

Today ZURA has the market capitalization of 261.39M USD.